izpis_h1_title_alt

Cannabinoids and triple-negative breast cancer treatment
ID Dobovišek, Luka (Author), ID Borštnar, Simona (Author), ID Debeljak, Nataša (Author), ID Kranjc Brezar, Simona (Author)

.pdfPDF - Presentation file, Download (1,10 MB)
MD5: DA666E120BC28ACBE07BF76A7E32A232
URLURL - Source URL, Visit https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1386548/full This link opens in a new window

Abstract
Triple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC were limited to chemotherapy. A new successful systemic treatment is immunotherapy with immune checkpoint inhibitors, but new tumor-specific biomarkers are needed to improve patient outcomes. Cannabinoids show antitumor activity in most preclinical studies in TNBC models and do not appear to have adverse effects on chemotherapy. Clinical data are needed to evaluate efficacy and safety in humans. Importantly, the endocannabinoid system is linked to the immune system and immunosuppression. Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy. In this article, we provide an overview of the currently available information on how cannabinoids may influence standard therapy in TNBC.

Language:English
Keywords:triple-negative breast cancer, breast cancer, cancer treatment, cannabinoids
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication version:Version of Record
Publication date:01.08.2024
Year:2024
Number of pages:Str. 1-13
Numbering:Vol. 15
PID:20.500.12556/RUL-165016 This link opens in a new window
UDC:618.1
ISSN on article:1664-3224
DOI:10.3389/fimmu.2024.1386548 This link opens in a new window
COBISS.SI-ID:204044547 This link opens in a new window
Publication date in RUL:21.11.2024
Views:53
Downloads:5
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Frontiers in immunology
Shortened title:Front. immunol.
Publisher:Frontiers Research Foundation
ISSN:1664-3224
COBISS.SI-ID:30774233 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:trojno negativni rak dojke, rak dojke, onkološko zdravljenje, kanabinoidi

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003-2022
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-3062-2021
Name:Avtologni imunohibridomi in napredno zdravljenje trojno negativnega raka dojk stadijev II in III

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:L3-9279

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:L3-4511

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:PI-0390

Funder:Other - Other funder or multiple funders
Funding programme:University Medical Center Ljubljana
Project number:20170073

Funder:Other - Other funder or multiple funders
Funding programme:University Medical Centre Ljubljana
Project number:20200231

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back